TITLE:
Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis

CONDITION:
Aspergillosis

INTERVENTION:
Micafungin

SUMMARY:

      The purpose of this study is to evaluate the safety and effectiveness of micafungin in
      combination with AmBisome as first-line therapy in the treatment of invasive aspergillosis.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: N/A to N/A
Criteria:

        Inclusion Criteria

          -  Have proven or probable systemic infection with Aspergillus species and have received
             no more than 96 hours of prior therapeutic doses of systemic antifungal therapy

        Exclusion Criteria

          -  Has abnormal liver test parameters, e.g., AST or ALT > 10 times upper limit of normal

          -  Has allergic bronchopulmonary aspergillosis, aspergillomas, or with sinus
             aspergillosis or external otitis who do not have evidence of tissue invasion

          -  Has life expectancy of less than five days
      
